Rally Beats Expectations With $84M IPO, Shares to Trade This Morning

4/12/13Follow @MichaelXBD

Rally Software Development beat expectations for its IPO, scheduled this morning. The company raised $84 million.

Rally, a Boulder, CO-based company that develops cloud-based project management tools for software developers, set the price of its common stock at $14 per share and sold 6 million shares. Last week, Rally said it would offer 5.75 million shares priced between $11 and $13 per share.

Rally will trade on the NYSE as “RALY”.

Founded as F4 Technologies in 2001 by Ryan Martens, the company’s current chief technology officer, Rally has been one of the fastest-growing companies in Boulder and has a headcount around 380 employees companywide.

Rally has been showing strong revenue growth, according to financial data included in its IPO filing. From fiscal 2012 to fiscal 2013, Rally’s total revenue grew to $56.8 million, up 38 percent from $41.3 million. Revenue was $29.7 million during the company’s 2011 fiscal year.

Rally reported a $10.8 million net loss in 2013, down from the $11.6 million net loss the year before.

Investors in Rally include Boulder Ventures, Mobius Venture Capital, Greylock Partners, and Meritech Capital Partners.

Deutsche Bank Securities and Piper Jaffray & Co. acted as lead book-running managers for the offering. Needham & Company, JMP Securities, and William Blair & Company were co-managers.

Michael Davidson is the editor of Xconomy Boulder/Denver. He covers startups, venture capital, clean tech, energy, aerospace, telecoms, and whatever else happens above 5,280 feet. Contact him at mdavidson@xconomy.com. Follow @MichaelXBD

By posting a comment, you agree to our terms and conditions.

  • http://blogmutt.com Scott Yates

    Great day for Colorado tech companies!

  • Tangair

    No rally for RALY: One toe into an already overserved field and these guys will soon know what the word commodity means. Modest growth on extrapolation expectations and then a soft plateau. Not what I’d call a winning formula in an era of 18-month lifetimes.